This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
1,272
Patients self-administered fingolimod 1.25 mg capsules orally once daily.
Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Patients self-administered a fingolimod placebo capsule orally once daily.
Estimated Annualized Aggregate Relapse Rate (ARR)
The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.
Time frame: Baseline to end of study (Month 24)
Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.
Time frame: Baseline to end of study (Month 24)
Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline
The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
Time frame: Baseline to end of study (Month 24)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
North Gosford Private Hospital
Burrabil Avenue, Suite 17, Gosford, Australia
Strategic Health Evaluators
Chatswood, Australia
St Vincent's Hospital Melbourne, Department of Clinical Neurosciences
Fitzroy, Australia
Austin Health, Department of Neurology
Heidelberg, Australia
Algemeen Ziekenhuis St. Jan, Department of Neurology
Ruddershove, Brugge, Belgium
Erasme Hospital
Route de Lennik 808, Brussels Capital, Belgium
CHU Charleroi, Hôpital Civil
Boulevard Paul Janson 92, Charleroi, Belgium
University Hospital Gasthuisberg
Department Neurology, Herestraat 49, Leuven, Belgium
AZ Alma
Department of Neurology & Rehab-Umit, Gentsesteenweg 132, Sijsele, Belgium
...and 105 more locations